Hims & Hers Health (NYSE:HIMS) Shares Gap Up After Analyst Upgrade

Hims & Hers Health, Inc. (NYSE:HIMS)’s share price gapped up prior to trading on Thursday after Bank of America raised their price target on the stock from $21.00 to $25.00. The stock had previously closed at $24.29, but opened at $26.15. Bank of America currently has a neutral rating on the stock. Hims & Hers Health shares last traded at $25.3760, with a volume of 16,070,469 shares changing hands.

A number of other research analysts have also recently issued reports on the company. Needham & Company LLC raised Hims & Hers Health from a “hold” rating to a “buy” rating and set a $30.00 price target for the company in a report on Monday, March 9th. Zacks Research raised Hims & Hers Health from a “strong sell” rating to a “hold” rating in a report on Wednesday, February 25th. Wall Street Zen raised Hims & Hers Health from a “sell” rating to a “hold” rating in a report on Saturday, April 11th. Morgan Stanley dropped their price objective on Hims & Hers Health from $40.00 to $21.00 and set an “equal weight” rating for the company in a report on Tuesday, February 24th. Finally, Deutsche Bank Aktiengesellschaft boosted their price objective on Hims & Hers Health from $25.00 to $28.00 and gave the stock a “hold” rating in a report on Tuesday, March 10th. Three equities research analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $31.86.

Insider Transactions at Hims & Hers Health

In other Hims & Hers Health news, COO Michael Chi sold 97,289 shares of the business’s stock in a transaction dated Tuesday, March 17th. The stock was sold at an average price of $24.69, for a total transaction of $2,402,065.41. Following the completion of the sale, the chief operating officer directly owned 407,282 shares of the company’s stock, valued at approximately $10,055,792.58. The trade was a 19.28% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO Oluyemi Okupe sold 3,975 shares of the business’s stock in a transaction dated Monday, April 6th. The stock was sold at an average price of $19.98, for a total value of $79,420.50. Following the sale, the chief financial officer directly owned 318,789 shares of the company’s stock, valued at $6,369,404.22. This represents a 1.23% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 129,889 shares of company stock valued at $3,230,986. 13.71% of the stock is owned by company insiders.

Key Stories Impacting Hims & Hers Health

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: FDA begins a formal review to consider whether multiple peptide bulk drug substances can be used by compounding pharmacies — a change that could expand addressable market for telehealth sellers like Hims & Hers. Article Title
• Positive Sentiment: Comments from FDA leadership (and coverage noting RFK Jr.’s stance) signaled a regulatory pivot toward loosening peptide restrictions, boosting investor confidence in a policy-driven growth leg. Article Title
• Positive Sentiment: Bank of America raised its price target to $25 (Neutral rating) citing the FDA step as an early-stage catalyst that could meaningfully boost peptide revenue if regulatory changes proceed. Article Title
• Neutral Sentiment: Reuters and other outlets frame the move as a potential long‑term win but emphasize this is an early, advisory-stage process (PCAC meetings scheduled for July 23–24). Timing and final regulatory outcomes remain uncertain. Article Title
• Neutral Sentiment: Unusually large call-option activity was recorded recently, indicating elevated speculative interest and positioning around the regulatory story (high short‑term gamma/volatility risk).
• Negative Sentiment: Several analyst pieces note HIMS’ recent operational strains — the stock is down materially over six months, with margins and cash flow under pressure — which could blunt upside if peptide approval is delayed or narrower than hoped. Article Title

Institutional Trading of Hims & Hers Health

Institutional investors and hedge funds have recently modified their holdings of the stock. Pathway Capital Management LP bought a new stake in shares of Hims & Hers Health in the 3rd quarter valued at about $6,766,000. Steadview Capital Management LLC increased its stake in shares of Hims & Hers Health by 80.0% in the 3rd quarter. Steadview Capital Management LLC now owns 701,845 shares of the company’s stock valued at $39,809,000 after acquiring an additional 311,845 shares during the last quarter. BIT Capital GmbH increased its stake in shares of Hims & Hers Health by 73.8% in the 3rd quarter. BIT Capital GmbH now owns 2,210,384 shares of the company’s stock valued at $125,373,000 after acquiring an additional 938,728 shares during the last quarter. Farallon Capital Management LLC increased its stake in shares of Hims & Hers Health by 30.8% in the 3rd quarter. Farallon Capital Management LLC now owns 10,746,852 shares of the company’s stock valued at $609,561,000 after acquiring an additional 2,533,271 shares during the last quarter. Finally, State of Michigan Retirement System increased its stake in shares of Hims & Hers Health by 49.2% in the 3rd quarter. State of Michigan Retirement System now owns 2,057,700 shares of the company’s stock valued at $116,713,000 after acquiring an additional 678,600 shares during the last quarter. 63.52% of the stock is owned by institutional investors.

Hims & Hers Health Trading Up 11.4%

The company has a current ratio of 1.90, a quick ratio of 1.70 and a debt-to-equity ratio of 1.80. The company has a market capitalization of $6.17 billion, a P/E ratio of 53.05, a PEG ratio of 2.31 and a beta of 2.32. The business has a 50 day moving average price of $19.60 and a 200 day moving average price of $32.66.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings results on Monday, February 23rd. The company reported $0.08 EPS for the quarter, beating analysts’ consensus estimates of $0.02 by $0.06. The company had revenue of $617.82 million during the quarter, compared to analysts’ expectations of $619.48 million. Hims & Hers Health had a return on equity of 22.48% and a net margin of 5.47%.Hims & Hers Health’s revenue was up 28.4% on a year-over-year basis. During the same period in the prior year, the business posted $0.11 EPS. Analysts anticipate that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.